Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

ABBOTT, BAXTER AND AHSC COLLABORATING ON AT-HOME ANTIBIOTIC infusion therapy reimbursement effort through a project run under the auspices of the Health Industry Manufacturers Assn. (HIMA). The three companies are funding an effort to collect background information for soliciting govt. reimbursement. The first step in the project was the selection of Pierson, Ball & Dowd as the law firm to examine legal precedents for reimbursement coverage and Lewin and Associates as a consulting firm to prepare economic arguments. HIMA is acting as the coordinating body for the project and has contracted with the two advisors. However, the three specific members are paying for the project through a special assessment. A non-HIMA member, Caremark, is also reportedly interested in participating in the project. The joint effort indicates the increasing awareness among hospital supply companies of the importance of coverage/reimbursement decisions as the initial step in developing a new technology market. The three companies are working together on the spadework to expand the common market in which they compete. The companies are beginning the effort to convince the Health Care Financing Administration to extend Medicare coverage and reimbursement to at-home antibiotic therapy with a realistic view of the difficulties. Baxter, for example, commented in its annual report that "concerns about expanding patient populations have caused many governments to adopt conservative, and sometimes inadequate, policies towards reimbursement." If the companies fail to convince HCFA to allow coverage, they may seek the legislative route to have at-home antibiotic therapy covered.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts